Atezolizumab Injection · Oncology Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity.
FOLFOX4 or XELOX · Oncology FOLFOX4 and XELOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluoropyrimidine and platinum-based cytotoxic agents.
induction chemotherapy (mDCF) · Oncology mDCF is a combination chemotherapy regimen that uses docetaxel, cisplatin, and fluorouracil to inhibit cancer cell division and induce apoptosis in gastric and esophageal cancers.
Ipilimumab Injection · Oncology Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
liposomal cisplatin · Oncology Liposomal cisplatin works by releasing cisplatin, a platinum-based chemotherapy drug, in a targeted manner to kill cancer cells.
LV5FU2 or capecitabine · Oncology LV5FU2/capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase and gets incorporated into DNA/RNA, disrupting cancer cell replication.
LV5FU2 or capectitabine · Oncology LV5FU2 and capecitabine are fluoropyrimidine chemotherapy agents that inhibit thymidylate synthase and get incorporated into DNA/RNA to disrupt cancer cell replication.
Oxaliplatin intra-arteriel · Oncology Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, delivered directly into the hepatic artery to maximize local concentration in liver tumors.
Oxaliplatin intravenous · Oncology Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication and induce apoptosis.
FOLFIRI.3 · Oncology FOLFIRI is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, irinotecan, and folinic acid to target rapidly dividing cancer cells.